MedTrace Logo

Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

NCT07773532 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 115

Last updated 2026-08-19

No results posted yet for this study

Summary

Overactive bladder (OAB) is associated with systemic chronic inflammation. Indices derived from complete blood count (such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII)) have shown associations with OAB presence. However, whether baseline inflammatory status predicts response to beta-3 adrenergic agonist therapy remains untested. This prospective observational cohort study evaluates the predictive ability of baseline NLR, PLR, and SII for 3-month treatment response to mirabegron 50 mg in women with OAB.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

Mirabegron (beta3-adrenoceptor agonist)

Mirabegron 50 mg orally once daily, initiated and managed by the treating physician as part of routine clinical care. The drug is not assigned by the study protocol; the study observes patients in whom this treatment has been started within standard practice.

Sponsors & Collaborators

  • Bagcilar Training and Research Hospital

    lead OTHER_GOV

Principal Investigators

  • Özgür Aslan, MD · Bagcilar Training and Research Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2027-10-01
Completion
2027-11-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07773532 on ClinicalTrials.gov